23andme co-founder and former CEO Anne Wozikki is ready to buy the company back after filing chapter 11 for insolvency conservation earlier this year. On Friday, 23andme and TTAM Research Institute, a non -profit public advantage corporation operated by Wojcicki, Announced in a press release Ttam must be buying “all of the company’s assets” for $ 305 million.

By last month, New York -based Biotech company Regenron Pharmaceuticals were set to buy 23andme For $ 256 millionBut the new purchase agreement with TTAM is the result of the last round of the first dialect between TTAM and Regenteron Pharmaceuticals, according to the release, “according to the release. Wojcicki made a “unwanted proposal” earlier this month, As The Wall Street Journal,

23andme is well known to your home genome test kit, and at a point the company was priced around 6 billion dollars, According to CNBCBut it has so far been unable to turn on a profit and deal with large -scale data violations In 2023Company paid $ 30 million Prosecute On last year’s violation. When 23andme filed for bankruptcy in MarchWojcicki resigns As CEO,

TTAM will comply with 23andme’s “privacy policies and applied laws” and created a “additional consumer security and privacy security measures”, including the establishment of a consumer privacy advisory board within about 90 days of the deal. The release states that the transaction is still under court approval, but “expected to be closed in the coming weeks.”